Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

about

Malignancies in women with HIV infection.

P2860

Q39010145-39F8DF61-A7DF-462A-83D5-C775F15AB428

P2860

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

Item

http://www.wikidata.org/entity/Q35865134

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@ast

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@en

type

Item

label

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@ast

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@en

prefLabel

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@ast

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@en

P1476

Cost-effectiveness analysis of ...... nodeficiency virus prevalence.

@en

P2093

Georges Van Kriekinge

http://www.w3.org/2001/XMLSchema#string

Martinus P Stander

http://www.w3.org/2001/XMLSchema#string

Nadia Demarteau

http://www.w3.org/2001/XMLSchema#string

Xiao Li

http://www.w3.org/2001/XMLSchema#string

P2860

Human papillomavirus vaccines: WHO position paper, October 2014

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women.

The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia, Africa.

Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women.

The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research

P2888

s12879-015-1295-z

P304

566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12879-015-1295-Z

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286627785

http://www.w3.org/2001/XMLSchema#string

P6179

1052491953

http://www.w3.org/2001/XMLSchema#string

P698

26652918

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

P932

4676856

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

about

P2860

P2860

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932